LEXINGTON, Mass. (AP) _ Dicerna Pharmaceuticals Inc. (DRNA) on Tuesday reported a loss of $17.1 million in its third quarter.

The Lexington, Massachusetts-based company said it had a loss of 22 cents per share.

The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 41 cents per share.

The biopharmaceutical company posted revenue of $63 million in the period, also beating Street forecasts. Four analysts surveyed by Zacks expected $58.8 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on DRNA at https://www.zacks.com/ap/DRNA

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News